These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16823838)
1. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Gafner V; Trachsel E; Neri D Int J Cancer; 2006 Nov; 119(9):2205-12. PubMed ID: 16823838 [TBL] [Abstract][Full Text] [Related]
2. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Kaspar M; Trachsel E; Neri D Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424 [TBL] [Abstract][Full Text] [Related]
3. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Melkko S; Halin C; Borsi L; Zardi L; Neri D Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1485-90. PubMed ID: 12459375 [TBL] [Abstract][Full Text] [Related]
4. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354 [TBL] [Abstract][Full Text] [Related]
5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649 [TBL] [Abstract][Full Text] [Related]
7. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. Ongaro T; Matasci M; Cazzamalli S; Gouyou B; De Luca R; Neri D; Villa A J Biotechnol; 2019 Feb; 291():17-25. PubMed ID: 30586544 [TBL] [Abstract][Full Text] [Related]
8. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Ebbinghaus C; Ronca R; Kaspar M; Grabulovski D; Berndt A; Kosmehl H; Zardi L; Neri D Int J Cancer; 2005 Aug; 116(2):304-13. PubMed ID: 15800913 [TBL] [Abstract][Full Text] [Related]
9. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Hemmerle T; Neri D Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211 [TBL] [Abstract][Full Text] [Related]
10. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281 [TBL] [Abstract][Full Text] [Related]
12. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Demartis S; Tarli L; Borsi L; Zardi L; Neri D Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506 [TBL] [Abstract][Full Text] [Related]
13. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Lo KM; Lan Y; Lauder S; Zhang J; Brunkhorst B; Qin G; Verma R; Courtenay-Luck N; Gillies SD Cancer Immunol Immunother; 2007 Apr; 56(4):447-57. PubMed ID: 16874486 [TBL] [Abstract][Full Text] [Related]
14. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Frey K; Zivanovic A; Schwager K; Neri D Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052 [TBL] [Abstract][Full Text] [Related]
15. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237 [TBL] [Abstract][Full Text] [Related]
16. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein. Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125 [TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292 [TBL] [Abstract][Full Text] [Related]
18. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083 [TBL] [Abstract][Full Text] [Related]
19. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049 [TBL] [Abstract][Full Text] [Related]
20. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Santimaria M; Moscatelli G; Viale GL; Giovannoni L; Neri G; Viti F; Leprini A; Borsi L; Castellani P; Zardi L; Neri D; Riva P Clin Cancer Res; 2003 Feb; 9(2):571-9. PubMed ID: 12576420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]